Skip to main navigation
Syndax
Main navigation
  • About
    • Back
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Vision, Mission, and Values
  • Pipeline
    • Back
    • Pipeline Overview
    • Revumenib
    • Axatilimab
    • Entinostat
    • Publications & Meeting Presentations
  • Clinical Trials
    • Back
    • Clinical Trials Overview
    • Revumenib Clinical Trials
      • Back
      • AUGMENT-101 (monotherapy)
      • AUGMENT-102 (chemo combo)
    • Axatilimab Clinical Trials
    • Compassionate Use
  • Patients & Caregivers
  • Investors
    • Back
    • Investors Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Back
      • Governance Overview
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financial Information
      • Back
      • Financial Overview
      • SEC Filings
      • Annual Reports and Proxies
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Back
      • Stock Overview
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • FAQs
    • Contact Us
  • Join Us
Syndax
Contact Us
Main navigation
  • About
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Vision, Mission, and Values
  • Pipeline
    • Pipeline Overview
    • Revumenib
    • Axatilimab
    • Entinostat
    • Publications & Meeting Presentations
  • Clinical Trials
    • Clinical Trials Overview
    • Revumenib Clinical Trials
      • AUGMENT-101 (monotherapy)
      • AUGMENT-102 (chemo combo)
    • Axatilimab Clinical Trials
    • Compassionate Use
  • Patients & Caregivers
  • Investors
    • Investors Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financial Information
      • Financial Overview
      • SEC Filings
      • Annual Reports and Proxies
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Stock Overview
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • FAQs
    • Contact Us
  • Join Us

Investors

 

Press Releases

09.09.10

Syndax Pharmaceuticals to Present at R.W. Baird 2010 Healthcare Conference and BioPharm America 2010

08.11.10

Syndax Pharmaceuticals raises $6 Million in Securities Offering

06.04.10

Syndax Pharmaceuticals' Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer

05.24.10

Syndax Pharmaceuticals Inc. to Present Entinostat Data Showing Benefit in Combination in Advanced Breast Cancer at ASCO

06.06.07

FierceBiotech Names Syndax Pharmaceuticals as One of the "Fierce 15" Biotech Companies of 2007

04.13.07

Syndax Pharmaceuticals Inc. Licenses Selective Histone Deacetylase Inhibitor MS-275

04.03.07

Syndax Pharmaceuticals Inc. closes $40 Million Series A Financing

Pagination

  • First page « first
  • Previous page ‹ previous
  • …
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Current page 22

Shareholder Tools

  • Printed Materials
  • Downloads
  • Email Alerts
  • RSS
  • Print
  • Share
  • Search

  • Facebook
  • Google
  • LinkedIn
  • Twitter
  • RSS
© 2023 Syndax | Terms of Use | Privacy Policy | Site Map
  • About Us
  • Pipeline
  • News
  • Investors
  • Careers